UFP Technologies, Inc. reported first‑quarter 2026 results that included $154.2 million in revenue, a 4.1% year‑over‑year increase, and adjusted earnings per share of $2.48, beating the consensus estimate of $2.18 by $0.30 (13.8%). GAAP earnings per share were $2.24, and net income reached $17.5 million.
Revenue growth was driven by a 5.9% rise in medical sales, which offset a 15% decline in non‑medical sales. Within the medical portfolio, robotic surgery revenue grew 7%, patient surfaces and support grew 11%, and interventional products grew 15%, underscoring the company’s shift toward higher‑margin MedTech segments.
Gross margin expanded to 28.8% from 28.5% in the prior year, while operating income increased modestly to $23.4 million from $23.1 million, a 1% year‑over‑year gain. The small operating income lift reflects the near‑flat margin improvement and the minimal impact of the mix shift on operating leverage.
CEO R. Jeffrey Bailly said, "I am pleased with our first quarter results and continued progress with our strategic initiatives." He added, "Revenue grew 4.1%, driven by a 5.9% increase in our medical sales. This was offset by a 15% decline in our non‑medical sales as we continue to focus our efforts on high‑growth opportunities in the MedTech space." The company also announced that it will take possession of two new facilities in the Dominican Republic in Q2 to support growth in robotic surgery and safe patient handling.
The results illustrate the company’s successful transition from a foam fabricator to a MedTech contract manufacturer. The EPS beat was largely due to strict cost controls and a favorable product mix, while the slight revenue miss was attributable to the decline in legacy non‑medical sales and the impact of E‑Verify labor‑inefficiency costs at the AJR operation. Management noted that start‑up expenses for four ramping programs were absorbed this quarter, which helped keep earnings on track.
Investors reacted with mixed sentiment, weighing the earnings beat against the revenue miss and the company’s ongoing strategic investments.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.